NEW YORK (TheStreet) -- Halozyme Therapeutics (HALO) shares are rocketing up 14.1% to $9.22 following the announcement that the FDA lifted a hold on the clinical study of its pancreatic cancer treatment.
The FDA ruled that the mid-stage study of the drug PEGPH20 can resume.
The study is designed to measure the progression-free survival time in patients with advanced stages of pancreatic cancer being treated with PEGPH20, compared to patients being treated solely with chemotherapy.
Must Read: Warren Buffett's 25 Favorite Stocks
TheStreet Ratings team rates HALOZYME THERAPEUTICS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:
"We rate HALOZYME THERAPEUTICS INC (HALO) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share."